Galapagos changed course earlier this year, announcing it no longer wanted to focus on cell therapy and would seek buyers for this business. After shopping around the assets for months, Galapagos ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...

The Galapagos pipeline spans both oncology and immunology, but in recent years, the company has invested heavily in cancer cell therapy. The firm is now fully embracing the modality, announcing on ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos The plan would enable the ...

K orea-based biotechnology company Nature Cell plans to open a manufacturing facility in Baltimore City, Maryland. The approximately 100,000-square-foot operation at the Gaslight Square mixed-use ...

Positive RG6501 (OpRegen ®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, ...